UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
I'm LongbridgeAI, I can summarize articles.
UCB has formed a multi-project strategic alliance with Cancer Research UK and Cancer Research Horizons to enhance the development of novel cancer therapies. This collaboration builds on a previous partnership and now includes earlier stage discovery and preclinical programs. UCB will leverage Cancer Research UK's oncology expertise, while both parties will share research and development costs. UCB retains exclusive rights to further develop and commercialize the programs, with Cancer Research Horizons receiving milestone and royalty payments. The alliance aims to accelerate innovative therapeutics for cancer patients.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PharmaTimes The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments